Herpes zoster vaccine (Zostavax).
A live attenuated varicella-zoster vaccine (Zostavax--Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons > or = 60 years old. Each dose of Zostavax contains about 14 times as much varicella-zoster virus (VZV) as Varivax, which has been used in the US since 1995 to vaccinate against varicella (chicken pox).
D000328:Adult; D000367:Age Factors; D017277:Drug Approval; D006562:Herpes Zoster / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D053061:Herpes Zoster Vaccine; D022283:Herpesvirus Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D051474:Neuralgia, Postherpetic / Q000209:etiology; D011159:Population Surveillance; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors; D014481:United States; D014613:Vaccines, Attenuated / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use
D053061:Herpes Zoster Vaccine; D022283:Herpesvirus Vaccines; D014613:Vaccines, Attenuated